Brivaracetam

Chembox new
ImageFileL1 = Brivaracetam.png ImageSizeL1 = 100px
ImageFileR1 = Brivaracetam3d.png ImageSizeR1 = 110px
IUPACName = (2S)-2- [(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide
OtherNames =
Section1 = Chembox Identifiers
PubChem =
CASNo =
ATCCode_prefix =
ATCCode_suffix =
SMILES=
Section2 = Chembox Properties
Formula = | C=11 | H=20 | N=2 | O=2
MolarMass = 212.153 g/mol
Appearance =
Density =
MeltingPt =
BoilingPt =
Solubility =
Section5 = Chembox Pharmacology
AdminRoutes = Oral
Bioavail =
Metabolism =
HalfLife =
ProteinBound =
Excretion =
Legal_status =
Legal_US =
Legal_UK =
Legal_AU =
Legal_CA =
PregCat =
PregCat_AU =
PregCat_US =

Brivaracetam, the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. [cite journal |author=von Rosenstiel P |title=Brivaracetam (UCB 34714) |journal=Neurotherapeutics |volume=4 |issue=1 |pages=84–7 |year=2007 |pmid=17199019 |doi=10.1016/j.nurt.2006.11.004] [cite journal |author=Malawska B, Kulig K |title=Brivaracetam UCB |journal=Curr Opin Investig Drugs |volume=6 |issue=7 |pages=740–746 |year=2005 |pmid=16044671] Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle protein SV2. [cite journal | author=Rogawski MA, Bazil CW |title=New molecular targets for antiepileptic drugs: α2δ, SV2A, and K(v)7/KCNQ/M potassium channels |journal=Curr Neurol Neurosci Rep |year=2008 |volume=8 |issue=4 |pages=345-352 |pmid=18590620] Phase II clinical trials in adult patients with refractory partial seizures were promising. The drug is currently undergoing Phase III clinical trials. [cite journal |author=Rogawski M |title=Brivaracetam: a rational drug discovery success story |journal=Br J Pharmacol |year=2008 |pmid=18552880 |doi=10.1038/bjp.2008.221]

References